1. Iglesias, A, Bauer, J, Litzenburger, T, et al. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001; 36: 220–234.
Google Scholar | Crossref | Medline2. Lebar, R, Baudrimont, M, Vincent, C. Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease. J Autoimmun 1989; 2: 115–132.
Google Scholar | Crossref | Medline3. Ramanathan, S, Dale, RC, Brilot, F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016; 15: 307–324.
Google Scholar | Crossref | Medline | ISI4. Jarius, S, Paul, F, Aktas, O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018; 15: 134.
Google Scholar | Crossref | Medline5. Lopez-Chiriboga, AS, Majed, M, Fryer, J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 2018; 75: 1355–1363.
Google Scholar | Crossref | Medline6. Jarius, S, Ruprecht, K, Kleiter, I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13: 280.
Google Scholar | Crossref7. Jurynczyk, M, Messina, S, Woodhall, MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017; 140: 3128–3138.
Google Scholar | Crossref | Medline8. Cobo-Calvo, A, Ruiz, A, Maillart, E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018; 90: e1858–e1869.
Google Scholar | Crossref | Medline9. Kitley, J, Waters, P, Woodhall, M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276–283.
Google Scholar | Crossref | Medline | ISI10. Lopez-Chiriboga, S, Sechi, E, Buciuc, M, et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. JAMA Neurol 2020; 8: e203115.
Google Scholar11. Whittam, DH, Karthikeayan, V, Gibbons, E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol 2020; 267: 3565–3577.
Google Scholar | Crossref | Medline12. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
Google Scholar | Crossref | Medline | ISI13. Stroup, DF, Berlin, JA, Morton, SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
Google Scholar | Crossref | Medline | ISI14. Rostom, A, Dubé, C, Cranney, A, et al. Celiac disease. Rockville, MD: Agency for Healthcare Research and Quality (US), 2004 (Evidence reports/technology assessments, no. 104. Appendix D. Quality assessment forms), https://www.ncbi.nlm.nih.gov/books/NBK35156/
Google Scholar15. Wan, X, Wang, W, Liu, J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
Google Scholar | Crossref | Medline | ISI16. Montcuquet, A, Collongues, N, Papeix, C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 2017; 23: 1377–1384.
Google Scholar | SAGE Journals | ISI17. Ramanathan, S, Mohammad, S, Tantsis, E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018; 89: 127–137.
Google Scholar | Crossref | Medline18. Cobo-Calvo, A, Sepulveda, M, Rollot, F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 2019; 16: 134.
Google Scholar | Crossref | Medline19. Mao, L, Yang, L, Kessi, M, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south China: clinical features, treatments, influencing factors, and outcomes. Front Neurol 2019; 10: 868.
Google Scholar | Crossref | Medline20. Zhou, J, Lu, X, Zhang, Y, et al. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination. Mult Scler Relat Disord 2019; 28: 4–10.
Google Scholar | Crossref | Medline21. Whittam, DH, Cobo-Calvo, A, Lopez-Chiriboga, AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord 2020; 44: 102251.
Google Scholar | Crossref | Medline22. Chen, JJ, Flanagan, EP, Bhatti, MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020; 95: e111–e120.
Google Scholar | Crossref | Medline23. Albassam, F, Longoni, G, Yea, C, et al. Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease. Dev Med Child Neurol 2020; 62: 390–395.
Google Scholar | Crossref | Medline24. Tzartos, JS, Karagiorgou, K, Tzanetakos, D, et al. Deciphering anti-MOG IgG antibodies: clinical and radiological spectrum, and comparison of antibody detection assays. J Neurol Sci 2020; 410: 116673.
Google Scholar | Crossref | Medline25. Pedapati, R, Bhatia, R, Singh, N, et al. Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum – a north Indian tertiary care centre experience and review of literature. J Neuroimmunol 2020; 340: 577143.
Google Scholar | Crossref | Medline26. Durozard, P, Rico, A, Boutiere, C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 2020; 87: 256–266.
Google Scholar | Crossref | Medline27. Holmoy, T, Hoglund, RA, Illes, Z, et al. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. Epub ahead of print 3 October 2020. DOI: 10.1007/s00415-020-10235-5.
Google Scholar | Crossref | Medline28. Hauser, SL, Cree, B. Treatment of multiple sclerosis: a review. Am J Med 2020; 133: 1380–1390.
Google Scholar | Crossref | Medline29. Rastetter, W, Molina, A, White, CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477–503.
Google Scholar | Crossref | Medline | ISI30. Iorio, R, Damato, V, Alboini, PE, et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262: 1115–1119.
Google Scholar | Crossref | Medline | ISI31. Nepal, G, Shing, YK, Yadav, JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis. Acta Neurol Scand 2020; 142: 449–459.
Google Scholar | Crossref | Medline32. Damato, V, Evoli, A, Iorio, R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016; 73: 1342–1348.
Google Scholar | Crossref | Medline | ISI33. Tian, X, Chen, C, Ma, L, et al. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol 2020; 347: 577317.
Google Scholar | Crossref | Medline34. Gao, F, Chai, B, Gu, C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019; 19: 36.
Google Scholar | Crossref | Medline35. Reindl, M, Waters, P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019; 15: 89–102.
Google Scholar | Crossref | Medline36. Armangue, T, Olive-Cirera, G, Martinez-Hernandez, E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020; 19: 234–246.
Google Scholar | Crossref | Medline37. Lu, Q, Luo, J, Hao, H, et al. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol. Epub ahead of print 30 September 2020. DOI: 10.1007/s00415-020-10236-4.
Google Scholar | Crossref38. Villarroel, MC, Hidalgo, M, Jimeno, A. Mycophenolate mofetil: an update. Drugs Today 2009; 45: 521–532.
Google Scholar | Medline | ISI39. Allison, AC, Eugui, EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118.
Google Scholar | Crossref | Medline | ISI40. Huang, W, Wang, L, Zhang, B, et al. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord 2019; 35: 246–252.
Google Scholar | Crossref | Medline41. Li, S, Ren, H, Xu, Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm 2020; 7: e705.
Google Scholar | Crossref | Medline42. Hacohen, Y, Wong, YY, Lechner, C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018; 75: 478–487.
Google Scholar | Crossref | Medline43. Hegen, H, Reindl, M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord 2020; 13: 1756286420945135.
Google Scholar | SAGE Journals | ISI44. Sahasranaman, S, Howard, D, Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753–767.
Google Scholar | Crossref | Medline | ISI45. Espiritu, AI, Pasco, P. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 2019; 33: 22–32.
Google Scholar | Crossref | Medline46. Matney, SE, Huff, DR. Diagnosis and treatment of myasthenia gravis. Consult Pharm 2007; 22: 239–248.
Google Scholar | Crossref | Medline47. Hermetter, C, Fazekas, F, Hochmeister, S. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. Front Neurol 2018; 9: 706.
Google Scholar | Crossref | Medline